Dermatology and Therapy (Nov 2023)

Comorbidity Burden and Treatment Patterns of Psoriasis in Vietnam: Real-World Data from the EXPAND Study

  • Hao Trong Nguyen,
  • Anh Tuan Vu,
  • Nhi Thi Uyen Pham,
  • Tu Nguyen Anh Tran,
  • Nguyen Nhat Pham,
  • Huong Thi Thanh Bui,
  • Thuyen Thi Pham,
  • Vi Thi Thuy Dinh,
  • Yen Thi Bui,
  • Thao Thi Phuong Vu

DOI
https://doi.org/10.1007/s13555-023-01062-3
Journal volume & issue
Vol. 13, no. 12
pp. 3193 – 3208

Abstract

Read online

Abstract Introduction Psoriasis is a multi-faceted, immune-mediated inflammatory disease associated with a wide range of comorbidities. Real-world data on treatment patterns, comorbidities, and economic burden in patients with psoriasis are needed for comprehensive patient care in Vietnam. Methods A retrospective chart review study was conducted using secondary data extracted from patients’ medical records of two hospitals in Vietnam, with the aim of identifying adult patients with a confirmed diagnosis of psoriasis. The index date was defined as the date of first diagnosis between 1 January 2020 and 31 October 2021. Sociodemographic factors, disease characteristics, comorbidities, medication usage, drug survival, and medication costs were analyzed. Results A total of 661 patients were identified (mean ± standard deviation [SD] age 43.5 ± 14.8 years). The most prevalent comorbidity was dyslipidemia (49.6% of patients), followed by hypertension (23.4%), and psoriatic arthritis (10.4%). In total, 44% of patients received biologic therapies. Overall, 66.7% and 54.3% of patients receiving biologic and non-biologic therapies, respectively, had ≥ 1 comorbidity. Only 23.2% of patients with psoriasis-related comorbidities stopped therapy with biologics. Biologics had a longer retention time (17.0 months) than non-biologics (6.0 months) in patients with comorbidities. Patients with comorbidities had significantly higher total annual healthcare costs than those without comorbidities (in US dollars: USD901 vs. USD304; p < 0.001), mainly due to the relatively higher costs associated with the use of biologics. Conclusion Patients with psoriasis in Vietnam experience a high disease and economic burden due to comorbidities. Evidence from this real-world study supports the need for routine monitoring of and an appropriate treatment course for psoriasis-related comorbidities.

Keywords